Loading people...
John Keilty is a Venture Partner at Third Rock Ventures based in the Greater Boston Area. Prior to his current role, he served as Chief Data Sciences Officer at Decibel Therapeutics, which was acquired by Regeneron, and as Vice President of Information Management at Foundation Medicine, which was acquired by Roche. He previously spent nearly 13 years as Vice President of Information Technology and Informatics at Infinity Pharmaceuticals, and he began his career building genomic capabilities at Millennium Pharmaceuticals. Throughout his career, Keilty has contributed to two drug approvals, including Velcade and Coptra, and has been involved in launching and operating tens of companies such as Thrive and Inflection. His current focus centers on integrating advanced data science, computational biology, and technology roadmaps to scale early-stage biotechnology platforms and support drug discovery operations.
John Keilty is a distinguished Venture Partner at Third Rock Ventures, a premier venture capital firm renowned for its unique approach to company creation in the life sciences sector. His role is pivotal in identifying and nurturing the next generation of biotech companies poised to make significant impacts on human health.
As a Venture Partner, John provides critical strategic guidance and operational insights to Third Rock's portfolio companies. He is deeply involved in the firm's hands-on company building process, from concept generation and scientific validation to team formation and strategic development. This involves working closely with entrepreneurs and scientists to translate cutting-edge research into viable therapeutic platforms and products. His expertise helps shape the strategic direction of new ventures, ensuring they are well-positioned for success in a complex and rapidly evolving industry.
Third Rock Ventures, and by extension John Keilty's contributions, primarily focuses on creating and investing in companies that are developing novel medicines across a broad range of therapeutic areas. These often include oncology, immunology, neuroscience, rare diseases, and other areas of high unmet medical need. The firm's strategy emphasizes building companies from the ground up, often around breakthrough science or disruptive technologies, rather than simply investing in existing entities. John's involvement helps to identify the most promising scientific opportunities and guide their development into robust companies with clear paths to clinical impact.
John Keilty brings a wealth of experience to his role at Third Rock Ventures, reflecting a distinguished career within the biotechnology and pharmaceutical industries. While specific prior roles are proprietary, Venture Partners at Third Rock typically possess extensive leadership experience in drug discovery, development, or commercialization. This background equips them with a profound understanding of the scientific, operational, and regulatory challenges inherent in bringing new therapies to patients. John's career likely includes a strong track record of driving innovation, building high-performing teams, and successfully navigating the complexities of drug development, making him an invaluable asset to Third Rock's company creation model.
While specific individual investments led by John Keilty are not publicly detailed, his contributions are integral to the success of Third Rock Ventures' portfolio. The firm has a strong history of creating and incubating highly successful biotech companies that have gone on to develop significant therapeutic assets. John's strategic input and guidance play a crucial role in the early-stage development and ongoing success of these ventures, helping to shape companies that aim to deliver transformative medicines to patients worldwide. His work directly supports Third Rock's mission of building companies that address critical medical needs and push the boundaries of scientific innovation.
John Keilty is a Venture Partner at Third Rock Ventures, a leading life sciences venture capital firm. He plays a key role in identifying, building, and supporting innovative biotechnology companies focused on developing transformative medicines.
As a Venture Partner at Third Rock Ventures, John Keilty contributes to the firm's investments in early-stage life sciences companies. These companies typically focus on developing novel medicines across therapeutic areas such as oncology, immunology, neuroscience, and rare diseases, often built around breakthrough scientific platforms.
John Keilty works at Third Rock Ventures, a prominent venture capital firm dedicated to creating and investing in groundbreaking life sciences companies.
